Another study showed HER2/neu oncogene constructed DC vaccine and trastuzumab combination treatment prevented spontaneous mammary carcinoma growth in HER2/neu-overexpressing transgenic mice, as the combination treatment was able to induce strong HER2/neu-specific CD8+ CTL immunity, which prevented tumor growth in mice (126, 167). Here, ERBB2 is linked to breast carcinoma.